Algernon Pharmaceuticals Inc Class A (AGN)

CSE
0.090
0.000(0.00%)
  • Volume:
    193,250
  • Bid/Ask:
    0.090/0.095
  • Day's Range:
    0.090 - 0.095
  • Type:Equity
  • Market:Canada
  • ISIN:CA01559R1038
  • CUSIP:01559R103

AGN Overview

Prev. Close
0.09
Day's Range
0.09-0.095
Revenue
-
Open
0.095
52 wk Range
0.075-0.54
EPS
-0.08
Volume
193,250
Market Cap
15.07M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
226,923
P/E Ratio
-
Beta
0.12
1-Year Change
-70.97%
Shares Outstanding
167,486,769
Next Earnings Date
-
What is your sentiment on Algernon Pharmaceuticals Inc Class A?
or
Market is currently closed. Voting is open during market hours.

Algernon Pharmaceuticals Inc Class A News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellStrong SellStrong SellStrong Sell
SummarySellSellStrong SellStrong SellStrong Sell

Algernon Pharmaceuticals Inc Class A Company Profile

Algernon Pharmaceuticals Inc Class A Company Profile

Employees
0
Market
Canada

Algernon Pharmaceuticals Inc, formerly Breathtec Biomedical Inc, is a Canada-based drug development company. The Company is focused on the areas of nonalcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

Read More
  • Big news comin soon! Buckle up
    1
    • why we going down again?
      0
      • If you have already invested, then stay put.  Otherwise, it's a wait and see over the next 3 -6 months until positive results start moving towards some proven results which will ultimately lead to sales traction in various markets around the world.  No, a vaccine created in the UK, US or otherwise will not be the killer of ifenprodil treatments worldwide.  Expect to see above .50 and beyond for end of March of 2021.
        0
        • How about now?
          0
          • Anybody on the fence better load up now...
            0
            • Anybody on the fence better load up now...
              0
              • 09:30 Wed 05 Aug 2020Algernon says first patient dosed in Phase 2 study of Ifenprodil as a treatment in idiopathic pulmonary fibrosis and chronic cough
                2
                • Gonna pass 50 cents with new positive results soon
                  0
                  • This companies full of shit
                    4
                    • Algernon is starting to appear as a hidden gem among traditional BioTech 'buy and hope' purchases by the public.  Ifenprodil has been proven in the past, and is gaining more attention as a leading runner for 'treatment' of Covid-19 versus wishful thinking for a near term Vaccine/Cure.  Positive support for investigative trials in South Korea, Australia, Canada, and now the US is warming up as well.  Management has a strong position of awareness of the future outlook and complexities of the upcoming trials.  Minimum 6 month position recommended, with 12-18 months more realistic of expectations of turning a healthy return on your investment.  If you have the patience for the medium term, this could provide you with exceptional returns.
                      0
                      • How can they say they are cautioning that Ifenprodil is not expresing to treat covid 19 when they testing it to treat it....
                        0
                    • They got FDA clearance for Ifenprodil study
                      0
                      • My does my stock say 0.03 on portfolio but the stock is currently .34
                        0
                        • Mine also does. I nearly shit!
                          0
                        • Mike Ivanitzwhats going on haha
                          0
                        • My qtrade has corrected. Maybe a smallGlich
                          0
                      • Any recient news?
                        0
                        • Great buy, Covid study heating up and phase 2 for IPF plan and clinical study of its repurposed drug NP-120 is now approved in Australia.
                          0
                          • Good opportunity to buy again!
                            0
                            • health canada gives a green light...woohooo
                              1
                              • Where did you read this?
                                0
                              • on proactive investors website
                                0
                              • Thanks
                                0
                            • BUY!! BIG BUY!!
                              0
                              • hmmmm who's been in since .20
                                0
                                • went in...phase 3 about to begin ...power moveee
                                  0
                                  • Next week!
                                    0
                                    • It's happening guys, Hopefully lots of good news next week
                                      0
                                      • what do you think will become of there trials ? and will this stock be a money maker could we see this at 5 dollars anytime soon?
                                        0
                                    • what do you guys think it's a strong Buy right now ?
                                      0
                                      • What's happening with BTH
                                        0
                                        • any news?
                                          0
                                        • No nothing. I'm wondering if I should keep my shares with them
                                          0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.